Beta thalassemia
MONDO:0019402Beta-thalassemia (BT) is characterized by deficiency (Beta+) or absence (Beta0) of synthesis of the beta globin chains of hemoglobin (Hb).
Also known as: Beta thalassemia intermedia, Beta thalassemia minor, Thalassemias, beta-, erythroblastic anaemia, erythroblastic anemia, thalassemia major, thalassemia, Hispanic gamma-delta-beta
121 clinical trials for this condition and its sub-types, 73 tagged with Beta thalassemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Beta thalassemia
-
Beta-thalassemia HBB/LCRB 2 trials · 57 incl. sub-types
3 sub-types
- Beta-thalassemia major 49 trials
- Beta-thalassemia intermedia 9 trials
- Thalassemia minor 1 trial
-
Dominant beta-thalassemia 0 trials
-
Thalassemia, beta+, silent allele 0 trials
-
How does a blood disorder drug perform in everyday practice?
Knowledge-focused Stopped earlyThis study looks at how the drug luspatercept is used in real-world clinics for patients with lower-risk myelodysplastic syndromes (MDS) or beta-thalassemia. Researchers will track patient characteristics, treatments, and outcomes like reduced need for blood transfusions. The goa…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
New sickle cell drug pociredir enters early human testing
Knowledge-focused Stopped earlyThis early-stage study is testing a new drug called pociredir in 24 adults with sickle cell disease. Researchers want to see how the drug moves through the body and whether taking it with food changes its effects. The goal is to gather safety and dosing information, not to treat …
Phase 1 • Sponsor: Fulcrum Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC